YZi Labs, an investment firm backed by Binance founder Changpeng "CZ" Zhao, has publicly escalated a governance battle with CEA Industries (NASDAQ: BNC), accusing the company of implementing "anti-shareholder" and "stockholder-unfriendly" strategies. The conflict centers on CEA's adoption of a shareholder rights plan, commonly known as a "poison pill," and amendments to its corporate bylaws.
The dispute, outlined in regulatory filings with the U.S. Securities and Exchange Commission (SEC) and public statements on X, intensified in December 2025. YZi Labs, a significant stakeholder in the BNB-focused treasury company, contends these measures are designed to entrench the current board and hinder investors from initiating changes through written consent. "These steps impose unnecessary constraints and procedural burdens beyond Nevada law," YZi argued, warning they could expose the board to liability for failing fiduciary duties.
YZi Labs is pursuing a consent solicitation to expand CEA's board and elect a new slate of directors. The firm pointed to CEA's lackluster performance following a $500 million private investment round in July, despite steady appreciation in its key holding, BNB. YZi also highlighted public comments from CEA CEO David Namdar, who allegedly discussed contemplating other crypto assets like Solana (SOL) at an industry conference, raising alarms among shareholders committed to the BNB-centric Digital Asset Treasury (DAT) strategy.
In response to the activist pressure, CEA stated it reaffirmed its commitment to its BNB DAT strategy and had not launched competing projects. The company framed the poison pill and bylaw changes as protective measures for all stockholders. CEA's plan activates if an entity acquires 15% or more of the company's stock without board consent, allowing other shareholders to buy discounted shares to dilute the acquirer's stake.
Ella Zhang, head of YZi Labs, stated the firm remains dedicated to productive discussions and "promoting the integrity and the value of the BNB ecosystem." The clash marks a stark reversal from earlier enthusiasm around CEA's pivot from e-cigarette production, which had sparked a 600% share price surge. As of early January 2026, CEA's stock had fallen 36.67% over six months, contrasting with BNB's approximate 38% gain.
